India global research hub for diabetes and next-generation healthcare solutions has gained strong momentum, Union Minister of State Dr. Jitendra Singh announced on Friday. Specifically, over a dozen diabetes-related research projects are currently underway through the Department of Biotechnology (DBT) and CSIR under the Ministry of Science and Technology. Furthermore, Dr. Singh shared these insights while inaugurating RSSDI 2026 in Bengaluru before leading clinicians, academicians, and international researchers.
Indigenous healthcare breakthroughs and youth prevention
Dr. Singh noted that India’s vast population and genetic diversity create unique opportunities to build globally relevant medical solutions. However, he cautioned that preventing obesity and diabetes among Indian youth represents a vital national responsibility extending beyond the medical fraternity. Additionally, India has transformed from relying on external treatments to developing indigenous vaccines, antibiotics, biosimilars, and genetic therapies.
| Research & Innovation Area | Key Government & Startup Initiatives |
| Active Diabetes Projects | Over a dozen initiatives via DBT and CSIR |
| Indigenous Biosimilars | Progress in liraglutide and insulin Lispro |
| Next-Gen Insulin Delivery | Temperature-resilient insulin and startup oral insulin |
| Genomic & Precision Research | India Genome Study and molecular-level interventions |
Moreover, the minister highlighted that precision medicine and molecular interventions open fresh pathways for understanding and preventing Type 2 diabetes.
Public-private collaboration and affordable treatment
Dr. Singh invited deeper collaboration among government institutes, private researchers, clinicians, startups, and medical associations to accelerate healthcare innovation. Specifically, he praised startup efforts exploring oral insulin alongside institutional work on temperature-resilient insulin to simplify storage and transport.
Consequently, indigenous progress in biosimilars like liraglutide and insulin Lispro strengthens affordable treatment access nationwide. Therefore, as India global research hub for diabetes initiatives advance, the country has solidified its position as a frontline contributor to global medical science.

